Overview

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Status:
Recruiting

Trial end date:
2022-12-30

Target enrollment:

Participant gender:

Summary

The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. The investigators believe that modulating the tumor microenvironment with biologic agents like cabozantinib will have synergistic effect when combined with checkpoint-based immunotherapeutics like durvalumab in this patient population. This is a phase I/II, open label, multi-cohort trial looking at safety, tolerability and efficacy endpoints.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Anwaar Saeed

Collaborators:

AstraZeneca
Exelixis

Treatments:

Antibodies, Monoclonal
Durvalumab
Immune Checkpoint Inhibitors
Tremelimumab